Search For

Distinct adaptive strategies to cisplatin, vinblastine and gemcitabine in a panel of chemoresistant bladder cancer cell lines

Immune checkpoint inhibitors in hepatocellular carcinoma therapy: resistance mechanisms, liver transplantation challenges and management strategies

Targeting the hypoxia signaling pathway with nanomedicine to reverse immunotherapy resistance

Resistance signatures manifested in early drug response across cancer types and species

New advances in understanding the mechanisms and treatment challenges of ALK-targeted therapy resistance in lung cancer

ROS1 mutations promote an immunosuppressive tumor microenvironment via MYC to confer immune evasion in head and neck cancer

Lactylation: a novel driver of drug resistance in the tumor microenvironment

Super-enhancer inhibitors THZ2 and JQ1 reverse temozolomide resistance in glioblastoma by suppressing SE-driven SOX9 expression

Decoding breast cancer treatment resistance through genetic, epigenetic, and immune-regulatory mechanisms: from molecular insights to translational perspectives

CF10/LV overcomes acquired resistance to 5-FU/LV in colorectal cancer cells through downregulation of the c-Myc/ABCB5 axis

The next frontier in antibody-drug conjugates: challenges and opportunities in cancer and autoimmune therapy

Interactions between tumor microenvironment and resistance to transarterial and systemic treatments for HCC